triciribine has been researched along with gemcitabine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hou, J; Wang, L | 1 |
| Deng, M; Evans, D; Fang, Y; Gao, B; Kim, J; Lee, S; Liu, T; Lou, W; Lou, Z; Niu, N; Qin, B; Wang, L; Xie, F; Yu, J; Zhang, H | 1 |
2 other study(ies) available for triciribine and gemcitabine
| Article | Year |
|---|---|
FKBP5 as a selection biomarker for gemcitabine and Akt inhibitors in treatment of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Ribonucleosides; Tacrolimus Binding Proteins; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2012 |
HEATR1 Negatively Regulates Akt to Help Sensitize Pancreatic Cancer Cells to Chemotherapy.
Topics: Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mice, Nude; Minor Histocompatibility Antigens; Oncogene Protein v-akt; Pancreatic Neoplasms; Phosphorylation; Random Allocation; Ribonucleosides; RNA-Binding Proteins; Xenograft Model Antitumor Assays | 2016 |